PET/CT Radiomics Integrated with Clinical Indexes as A Tool to Predict Ki67 in Breast Cancer: A Pilot Study

Author:

Ding Hui1,Li Yan1,Liang Ting1,Liao Yuting2,Yu Xiao2,Duan Xiaoyi1,Shen Cong1

Affiliation:

1. The First Affiliated Hospital of Xi’an Jiaotong University

2. Clinical & technical Support,Philips Healthcare

Abstract

Abstract Background: Breast cancer (BC) represents the second cause of cancer-related death among women globally, and Ki67 was demonstrated as an important predictive biomarker in worse survival and neoadjuvant treatment in BC. This study aims to investigate the value of radiomics features derived from 18F-FDG PET/CT combined with clinical characteristics in predicting Ki67 in patients with BC. Methods: A total of 114 patients diagnosed as BC and examined using 18F-FDG PET/CT were included in this study. Patients were randomly separated into a training set (n = 79, with 55 cases of Ki67 + and 24 cases of Ki67-) and a validation set (n = 35, with 24 cases of Ki67 + and 11 cases of Ki67-) at a ratio of 7:3. Thirteen clinical characteristics and 704 radiomics features were extracted, and the univariance logistic analysis, max-Relevance and Min-Redundancy, the least absolute shrinkage and selection operator regression, and the Spearman test were applied for feature selection. Three models were developed, including the clinical model, the radiomics model, and the combined model, and a nomogram of the combined model was constructed. The predictive performance of all three models was examined by the receiver operating characteristic (ROC) curve. Clinical utility was validated by decision curve analysis (DCA). Results: The N stage, tumor morphology, maximal standard uptake value, and the longest diameter were significantly different in Ki67 + and Ki67- groups (P < 0.05) and were selected as the most discriminative clinical features. Eight radiomics features were selected for the radiomics model. In total, 7 radiomics and the above 4 clinical characteristics were selected for the combined model. The AUC of the combined model in the training and test group was 0.90 (95% Confidence Interval (CI): 0.82–0.97) and 0.81 (95% CI: 0.64–0.99), respectively. The combined model significantly outperformed the radiomics model and the clinical model alone (P < 0.05). The DCA curve showed the advantages of the combined model over the clinical model and radiomics model. Conclusions: The radiomics-derived features combined with the clinical features could effectively predict Ki67 expression in BC based on PET/CT images. Trial registration: This study was registered at ClinicalTrials Gov (number NCT05826197) on 7th, May 2023.

Publisher

Research Square Platform LLC

Reference22 articles.

1. Siegel RL, Miller KD, Jemal A, Cancer statistics. 2020. CA: a cancer journal for clinicians. 2020;70(1):7–30.

2. VEGFR3, and Ki67 in Human Breast Cancer Pathology and Five Year Survival;Baker E;Breast cancer: basic and clinical research,2019

3. The inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis;Gallardo A;Breast Cancer Res Treat,2018

4. Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer;Kilickap S;Asian Pac J cancer prevention: APJCP,2014

5. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival;Ishihara M;Oncology,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3